Cyril H Benes

Cyril H Benes

UNVERIFIED PROFILE

Are you Cyril H Benes?   Register this Author

Register author
Cyril H Benes

Cyril H Benes

Publications by authors named "Cyril H Benes"

Are you Cyril H Benes?   Register this Author

83Publications

3911Reads

50Profile Views

Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo.

Int J Cancer 2019 Jul 29. Epub 2019 Jul 29.

OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32598DOI Listing
July 2019

A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.

Breast Cancer Res Treat 2019 Apr 3;174(3):605-613. Epub 2019 Jan 3.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05079-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440812PMC
April 2019

Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets.

BMC Bioinformatics 2019 Feb 18;20(1):83. Epub 2019 Feb 18.

The Center of Cancer Research, Massachusetts General Hospital, 149 13th Street, Charlestown, MA, 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12859-019-2642-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378741PMC
February 2019

Potent and selective effect of the mir-10b inhibitor MN-anti-mir10b in human cancer cells of diverse primary disease origin.

PLoS One 2018 20;13(7):e0201046. Epub 2018 Jul 20.

Molecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0201046PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054402PMC
January 2019

A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors.

Cancer Res 2018 10 22;78(20):5949-5957. Epub 2018 Aug 22.

State Key Laboratory for Medical Genomics, Shanghai Institute of Hematology, Collaborative Innovation Center of Hematology, Collaborative Innovation Center of System Biology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-0455DOI Listing
October 2018

TP53 mutation status: emerging biomarker for precision radiation medicine?

Oncoscience 2018 Sep 28;5(9-10):258-259. Epub 2018 Aug 28.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncoscience.468DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231449PMC
September 2018

BRAF and AXL oncogenes drive RIPK3 expression loss in cancer.

PLoS Biol 2018 08 29;16(8):e2005756. Epub 2018 Aug 29.

Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pbio.2005756DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114281PMC
August 2018

Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer.

Cancer Res 2018 02 11;78(3):769-780. Epub 2017 Dec 11.

European Molecular Biology Laboratory - European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-17-1679DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522379PMC
February 2018

EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.

Cancer Cell 2018 02 18;33(2):202-216.e6. Epub 2018 Jan 18.

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108173056
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2017.12.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846483PMC
February 2018

Differential Effector Engagement by Oncogenic KRAS.

Cell Rep 2018 02;22(7):1889-1902

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1450 3rd Street, San Francisco, CA 94158, USA; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., P.O. Box B, Frederick, MD 21702, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2018.01.051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343826PMC
February 2018

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.

Cell Cycle 2017 Oct 10;16(19):1790-1799. Epub 2017 May 10.

a Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center , Philadelphia , PA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2017.1325046DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628644PMC
October 2017

Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities.

Nat Biotechnol 2017 Oct 11;35(10):983-989. Epub 2017 Sep 11.

Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Charlestown, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nbt.3955DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683351PMC
October 2017

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.

Oncotarget 2017 Oct 12;8(47):81776-81793. Epub 2017 Sep 12.

Department of Hematology/Oncology, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.20819DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669847PMC
October 2017

APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.

Cancer Res 2017 09 11;77(17):4567-4578. Epub 2017 Jul 11.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-16-3389DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609510PMC
September 2017

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.

PLoS One 2015 13;10(10):e0140310. Epub 2015 Oct 13.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, United States of America; Dermatology and Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140310PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604168PMC
June 2016

Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors.

Authors:
Cyril H Benes

Mol Cell Oncol 2015 Oct-Dec;2(4):e999504. Epub 2015 May 1.

Massachusetts General Hospital; Center for Cancer Research; Boston, MA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23723556.2014.999504DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905366PMC
June 2016

Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase.

Mol Cell 2015 Sep 10;59(6):1011-24. Epub 2015 Sep 10.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molcel.2015.07.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575890PMC
September 2015

Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers.

Mol Cancer Res 2015 Apr 9;13(4):713-20. Epub 2015 Feb 9.

Laboratory of Cellular and Molecular Radiation Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts. Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-14-0570DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410013PMC
April 2015

Lysine demethylase KDM4A associates with translation machinery and regulates protein synthesis.

Cancer Discov 2015 Mar 6;5(3):255-63. Epub 2015 Jan 6.

Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Charlestown, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-1326DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355328PMC
March 2015

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.

Science 2015 Jan;347(6219):273-7

Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA. Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.1257216DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358324PMC
January 2015

Drug/Cell-line Browser: interactive canvas visualization of cancer drug/cell-line viability assay datasets.

Bioinformatics 2014 Nov 6;30(22):3289-90. Epub 2014 Aug 6.

Department of Pharmacology and Systems Therapeutics, Systems Biology Center New York, Icahn School of Medicine at Mount Sinai, New York, NY 10029 and Center for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/bioinformatics/btu526DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221125PMC
November 2014

CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.

Cancer Res 2014 Jul 1;74(14):3947-58. Epub 2014 Jul 1.

Authors' Affiliation: Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2923DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122288PMC
July 2014

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.

Nature 2014 Jul 22;511(7511):616-20. Epub 2014 Jun 22.

1] Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA [2] Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature13393DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244910PMC
July 2014

EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.

Cancer Res 2014 May 19;74(10):2825-34. Epub 2014 Mar 19.

Authors' Affiliations: Department of Radiation Oncology, Massachusetts General Hospital; Center for Cancer Research, Massachusetts General Hospital Cancer Center; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Department of Radiation Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden; OncoRay-National Center for Radiation Research in Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden; Institute of Radiation Oncology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden; and Cancer Consortium (DKTK) Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-3157DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278592PMC
May 2014

EMT twists the road to PI3K.

Cancer Discov 2014 Feb;4(2):149-51

Department of Medicine and Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-1030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918580PMC
February 2014

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Cancer Discov 2014 Jan 25;4(1):42-52. Epub 2013 Oct 25.

1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School; 3Division of Gastroenterology, Department of Medicine, Tufts Medical Center; 4Department of Pathology, Massachusetts General Hospital, Boston; and 5Radiation Oncology, Steele Lab for Tumor Biology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973435PMC
January 2014

EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.

Cancer Res 2013 Oct 21;73(20):6254-63. Epub 2013 Aug 21.

Authors' Affiliations: Laboratory of Cellular & Molecular Radiation Oncology, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Charlestown; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; and Center for Cancer Research, Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts; Research Oncology, Genentech, Inc., South San Francisco, California; Department of Pharmaceutical Biology, Ludwig Maximilian University of Munich, Munich; and Center for Oncology, University Medical Center Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-0044DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823187PMC
October 2013

P2X(7) receptor antagonists display agonist-like effects on cell signaling proteins.

Biochim Biophys Acta 2011 May 21;1810(5):532-42. Epub 2011 Mar 21.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbagen.2011.03.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087820PMC
May 2011

The C2 domain of PKCdelta is a phosphotyrosine binding domain.

Cell 2005 Apr;121(2):271-80

Department of Medicine, Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2005.02.019DOI Listing
April 2005